These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22799018)

  • 21. Antiarrhythmic drug therapy for atrial fibrillation.
    Sardar MR; Saeed W; Kowey PR
    Cardiol Clin; 2014 Nov; 32(4):533-49. PubMed ID: 25443235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marine omega-3 highly unsaturated fatty acids: From mechanisms to clinical implications in heart failure and arrhythmias.
    Glück T; Alter P
    Vascul Pharmacol; 2016 Jul; 82():11-9. PubMed ID: 27080538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Atrial remodeling and anti-remodeling therapy in atrial fibrillation].
    Neumann T; Hölschermann H
    Dtsch Med Wochenschr; 2006 Apr; 131(16):884-7. PubMed ID: 16625482
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictive value of the heart rate reserve in patients with permanent atrial fibrillation treated according to a strict rate-control strategy.
    De Schryver N; Scavée C; Marchandise S; Pasquet A; de Meester C; le Polain de Waroux JB
    Europace; 2014 Aug; 16(8):1125-30. PubMed ID: 24599938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial fibrillation: rate versus rhythm control.
    Amani F; Smith ES
    J Ark Med Soc; 2005 Oct; 102(4):110-2. PubMed ID: 16265929
    [No Abstract]   [Full Text] [Related]  

  • 26. Rhythm control and increased risk of noncardiovascular death in the Atrial Fibrillation Follow-up Investigation of Rhythm Management trial.
    Boriani G; Biffi M; Mattioli S
    Circulation; 2004 Sep; 110(11):e307-8; author reply e307-8. PubMed ID: 15364827
    [No Abstract]   [Full Text] [Related]  

  • 27. [Interrelation between typical atrial flutter and atrial fibrillation: two sides of the same coin].
    Khubulava GG; Didenko MV
    Vestn Ross Akad Med Nauk; 2007; (5):19-22. PubMed ID: 17601036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation.
    Podd SJ; Freemantle N; Furniss SS; Sulke N
    Europace; 2016 Mar; 18(3):340-6. PubMed ID: 26462707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].
    Ravens U; Wettwer E; Schotten U; Wessel R; Dobrev D
    Herzschrittmacherther Elektrophysiol; 2006 Jun; 17(2):64-72. PubMed ID: 16786464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New directions in antiarrhythmic drug therapy for atrial fibrillation.
    Heijman J; Voigt N; Dobrev D
    Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decrease of the atrial fibrillatory rate, increased organization of the atrial rhythm and termination of atrial fibrillation by AZD7009.
    Aunes-Jansson M; Edvardsson N; Stridh M; Sörnmo L; Frison L; Berggren A
    J Electrocardiol; 2013; 46(1):29-35. PubMed ID: 23219385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents].
    Sugi K
    J Cardiol; 1999 Mar; 33 Suppl 1():59-64. PubMed ID: 10342138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Electrophysiological study of the anti-arrhythmic activity of delagil and its modifying effect in patients with paroxysmal atrial fibrillation].
    Danilenko AM; Gimrikh EO; Chekhov AM; Marochkin AS; Gushchin IV
    Kardiologiia; 1988 Feb; 28(2):77-8. PubMed ID: 3373954
    [No Abstract]   [Full Text] [Related]  

  • 34. Rate versus rhythm control for atrial fibrillation.
    Halsey C; Chugh A
    Cardiol Clin; 2014 Nov; 32(4):521-31. PubMed ID: 25443234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate versus rhythm control in atrial fibrillation: no one-size-fits-all.
    McClanahan AL; Curtis AB
    Expert Rev Cardiovasc Ther; 2010 Jul; 8(7):891-3. PubMed ID: 20602548
    [No Abstract]   [Full Text] [Related]  

  • 36. Measuring success in atrial fibrillation: Groping the elephant.
    Zivin A
    Heart Rhythm; 2010 May; 7(5):602-3. PubMed ID: 20170771
    [No Abstract]   [Full Text] [Related]  

  • 37. [Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation].
    Kanorskiĭ SG; Bodrikova VV; Kanorskaia IuS
    Kardiologiia; 2007; 47(12):39-44. PubMed ID: 18260977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From translation to integration: how to approach the complexity of atrial fibrillation mechanisms.
    Schotten U
    Cardiovasc Res; 2021 Jun; 117(7):e88-e90. PubMed ID: 34131703
    [No Abstract]   [Full Text] [Related]  

  • 39. [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].
    Hammwöhner M; D'Alessandro A; Dobrev D; Kirchhof P; Goette A
    Herzschrittmacherther Elektrophysiol; 2006 Jun; 17(2):73-80. PubMed ID: 16786465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiarrhythmic drugs in paroxysmal atrial fibrillation. When and how?].
    Lévy S; Ricard P; Yapo F; Mansouri C
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():19-24. PubMed ID: 8734159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.